KPV
Anti-Inflammatory Tripeptide · Alpha-MSH Fragment
KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH, making it ideal for inflammation management.
Overview
KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH, making it ideal for inflammation management.
Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling. Reduces pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression like steroids.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Reduces TNF-α and IL-6 through NF-κB pathway inhibition.
May help balance overactive immune responses in autoimmune conditions.
Potential benefits for inflammatory arthritis through cytokine reduction.
Demonstrated benefit in Crohn's disease and ulcerative colitis models.
Helps restore intestinal barrier function.
Selective antimicrobial activity preserves beneficial gut bacteria.
Topical KPV reduced psoriatic markers by 60% and improved skin barrier function.
Reduces inflammatory skin conditions without systemic effects.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Tripeptide
- Chain length
- 3 residues
- Half-life
- ~1.5 h
- Typical dose
- 200-500 mcg per injection
- Frequency
- 1-2 times daily (once for maintenance, twice for active inflammation)
- Cycle length
- 4-8 weeks
- Storage
- Lyophilized: Room temperature. Reconstituted: 2-8°C, refrigerate immediately
Molecular data
- Type
- Tripeptide
- Chain length
- 3 residues
- Half-life
- 90 min
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| General anti-inflammatory | SubQ | 200-300mcg | Once daily |
| Active inflammation | SubQ | 250mcg | Twice daily |
| Autoimmune support | SubQ | 500mcg | Once daily |
| Acute flare-ups | SubQ | 500mcg | 2x daily for 1 week, then reduce |
| Gut health support | Mix in water/juice or enteric capsules | 200-500mcg | 2-3x daily |
| Skin inflammation | Affected skin areas | 0.1-0.5% cream/gel | 2-3x daily |
| Systemic anti-inflammatory | Nasal spray | 100-300mcg | 2-3x daily (1-2 sprays per nostril) |
Interactions
Enhanced gut healing and anti-inflammatory effects through complementary mechanisms.
Different mechanisms; can be combined safely.
Complementary antimicrobial and healing effects.
Both support immune function through different pathways.
Synergistic for skin health and regeneration.
Both are α-MSH related; KPV lacks pigmentation effects but monitor for cumulative effects.
Quality checklist
- ✓High purity >98%
- ✓Clear, colorless solution after reconstitution
- ✓Stable small peptide structure
- ✓Certificate of analysis available
- !pH should be 5.5-7 for optimal stability
- ×Visible particles indicate contamination/degradation
- ×Yellow coloration indicates oxidation/potency loss
What to expect
Safety
- Minimal to no side effects reported
- Does not cause immunosuppression like steroids
- No melanin production/tanning effects
- May temporarily reduce inflammation-related symptoms
- Signs of infection (fever, chills) - very rare
- Severe injection site reactions
- Paradoxical inflammation increase
- Allergic reaction symptoms
- Unusual fatigue or weakness
- Known peptide allergies
- Active severe infections (theoretical)
- Pregnancy or breastfeeding (limited data)
FAQ
Is KPV the same as alpha-MSH or melanotan?
No. KPV is the C-terminal tripeptide fragment of alpha-MSH, not the full hormone. Unlike melanotan, KPV provides anti-inflammatory benefits without causing melanin production or tanning. It's inflammation-focused, not pigmentation-focused.
Can I take KPV orally?
Yes. KPV is one of the few peptides with demonstrated oral bioavailability. It's transported into intestinal cells via PepT1 transporters, making oral capsules or dissolved powder viable alternatives to injection for gut health applications.
How quickly does KPV reduce inflammation?
Effects appear quickly—many users notice reduced inflammation within 1-3 days of starting. By week 1-2, inflammatory symptoms (joint pain, swelling, gut issues) typically show noticeable improvement. Full effects across inflammatory markers appear by week 4-6.
Can I use KPV for autoimmune conditions?
KPV shows promise for autoimmune modulation by reducing pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression. It may help balance overactive immune responses in conditions like Crohn's disease, but requires medical supervision and cannot replace standard treatments.
References
- 1Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal (KPV) Alpha-Melanocyte-Stimulating Hormone PeptidesGetting, S.J., Schiöth, H.B., Perretti, M. · Journal of Pharmacology and Experimental Therapeutics · 2003
Established that KPV exerts anti-inflammatory effects distinct from core MSH peptides, likely through inhibition of IL-1β functions rather than melanocortin receptor signaling.
reviewPubMed 12750433 ↗ - 2PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationDalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. · Gastroenterology · 2008
KPV inhibits NF-κB activation and reduces intestinal inflammation via PepT1-mediated transport; demonstrated anti-inflammatory effects in murine IBD models.
reviewPubMed 18061177 ↗ - 3Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel DiseaseKannengiesser, K., et al. · Inflammatory Bowel Diseases · 2008
KPV showed significant anti-inflammatory effects in DSS colitis and CD45RBhi transfer colitis models, reducing weight loss, histological damage, and MPO activity. Effects partially independent of MC1R signaling.
reviewPubMed 18092346 ↗ - 4Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of KPVViennois, E., et al. · Cellular and Molecular Gastroenterology and Hepatology · 2016
PepT1 is highly expressed in human colorectal tumors. PepT1-transported KPV prevented colitis-associated carcinogenesis in wild-type mice, with no effect in PepT1-knockout mice, confirming PepT1-dependent therapeutic mechanism.
animalPubMed 27458604 ↗ - 5Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative ColitisXiao, B., et al. · Molecular Therapy · 2017
HA-functionalized KPV nanoparticles (~272.3 nm) successfully targeted colonic epithelial cells and macrophages, exerting combined mucosal healing and anti-inflammatory effects superior to free KPV in a UC mouse model.
animalPubMed 28143741 ↗